MGV vs XBI
Vanguard Mega Cap Value ETF vs SPDR S&P Biotech ETF
- • MGV has the lower expense ratio at 0.05% vs 0.35% for XBI.
- • MGV pays a higher dividend yield (1.86%).
Side-by-side metrics
| Metric | MGV | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.05% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.86% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $13.31B | $10.73B |
YTD return | 16.36% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.66 | 1.10 |
P/E ratio | 22.84 | — |
Last price | $163.69 | $164.01 |
Inception | — | — |
Issuer | Vanguard | State Street |
MGV top holdings
| MU | Micron Technology Inc | 5.25% |
| JPM | JPMorgan Chase & Co | 3.63% |
| BRK-B | Berkshire Hathaway Inc Class B | 3.14% |
| XOM | Exxon Mobil Corp | 2.91% |
| JNJ | Johnson & Johnson | 2.61% |
| WMT | Walmart Inc | 2.44% |
| INTC | Intel Corp | 2.20% |
| CSCO | Cisco Systems Inc | 2.05% |
| COST | Costco Wholesale Corp | 2.04% |
| CAT | Caterpillar Inc | 1.96% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About MGV
MGV (Vanguard Mega Cap Value ETF) is Mega-cap US value stocks. Managed by Vanguard, the fund carries $13.3B in assets under management, an expense ratio of 0.05%, a dividend yield of 1.86%. Its largest holding is Micron Technology Inc (MU), which represents 5.2% of the portfolio. Real Estate is the fund's largest sector exposure at 1.2%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.